Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $928,800.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $61.92, for a total transaction of $928,800.00. Following the sale, the chief executive officer now owns 477,847 shares in the company, valued at approximately $29,588,286.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Grant Pickering also recently made the following trade(s):

• On Monday, March 25th, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.93, for a total transaction of $1,003,950.00.
• On Friday, March 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $73.70, for a total value of $192,799.20.
• On Thursday, February 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $73.91, for a total value of $193,348.56.
• On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.03, for a total value of $1,980,900.00.

Vaxcyte Price Performance

Shares of NASDAQ PCVX traded down $0.24 during trading hours on Thursday, hitting $60.06. 1,566,189 shares of the stock were exchanged, compared to its average volume of 842,040. Vaxcyte, Inc. has a one year low of $41.57 and a one year high of $82.04. The company’s 50 day moving average is $68.55 and its 200 day moving average is $61.28.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter in the previous year, the company posted ($0.73) earnings per share. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on PCVX. Bank of America boosted their target price on shares of Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research report on Wednesday, April 10th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $78.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PCVX. Parallel Advisors LLC grew its position in Vaxcyte by 155.3% in the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after acquiring an additional 250 shares during the period. Banque Cantonale Vaudoise grew its position in Vaxcyte by 96.7% during the 1st quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock worth $81,000 after acquiring an additional 582 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in Vaxcyte during the 3rd quarter valued at $178,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Vaxcyte in the fourth quarter valued at approximately $208,000. Finally, Rathbones Group PLC bought a new position in Vaxcyte in the 3rd quarter valued at $221,000. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.